Towa Pharmaceutical Co Ltd
TSE:4553
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.8), the stock would be worth ¥3 661.73 (8% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.9 | ¥3 960 |
0%
|
| 3-Year Average | 0.8 | ¥3 661.73 |
-8%
|
| 5-Year Average | 0.8 | ¥3 700.97 |
-7%
|
| Industry Average | 1.4 | ¥6 187.01 |
+56%
|
| Country Average | 1 | ¥4 390.15 |
+11%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Towa Pharmaceutical Co Ltd
TSE:4553
|
194.9B JPY | 0.9 | 9.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
910.2B USD | 9.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.2B USD | 2 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1 |
| 70th Percentile | 1.5 |
| Max | 23 050 349 |
Other Multiples
Towa Pharmaceutical Co Ltd
Glance View
Towa Pharmaceutical Co., Ltd. engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in Kadoma-Shi, Osaka-Fu and currently employs 3,456 full-time employees. The company went IPO on 2004-04-05. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. The company is a drug with the same effect, usage and dosage. The firm is involved in the sale and outsourced manufacture of products and generic drugs. The firm is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The firm is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
